Novel IκB kinase inhibitors for treatment of nuclear factor-κB-related diseases
暂无分享,去创建一个
[1] S. Ghosh,et al. Experimental Allergic Encephalomyelitis in the Adoptive Transfer Model of Essential Modifier-Binding Domain Peptides B k Antineuroinflammatory Effect of NF-Fung, , 2004 .
[2] K. Ziegelbauer,et al. Synthesis and structure–activity relationships of novel IKK-β inhibitors. Part 3: Orally active anti-inflammatory agents , 2004 .
[3] A. Itai,et al. Inhibition of IkappaB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury. , 2004, Cardiovascular research.
[4] M. Karin,et al. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. , 2000, Annual review of immunology.
[5] A. Smahi,et al. Inherited disorders of NF-kappaB-mediated immunity in man. , 2004, Current opinion in immunology.
[6] M. Karin,et al. Missing Pieces in the NF-κB Puzzle , 2002, Cell.
[7] J. Burke,et al. Collagen and Aggrecan Degradation Is Blocked in Interleukin-1-Treated Cartilage Explants by an Inhibitor of IκB Kinase through Suppression of Metalloproteinase Expression , 2005, Journal of Pharmacology and Experimental Therapeutics.
[8] J. Adams,et al. Novel IKK inhibitors: beta-carbolines. , 2003, Bioorganic & Medicinal Chemistry Letters.
[9] J. Adams,et al. Novel IKK inhibitors: β-carbolines , 2003 .
[10] K. McIntyre,et al. A highly selective inhibitor of I kappa B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. , 2003, Arthritis and rheumatism.
[11] L. Dang,et al. Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. , 2006, Oncogene.
[12] Michael Karin,et al. IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.
[13] Matthew S. Hayden,et al. New regulators of NF-κB in inflammation , 2008, Nature Reviews Immunology.
[14] M. Karin,et al. The two faces of IKK and NF-κB inhibition: prevention of systemic inflammation but increased local injury following intestinal ischemia-reperfusion , 2003, Nature Medicine.
[15] R. Weichselbaum,et al. Diverse TNFalpha-induced death pathways are enhanced by inhibition of NF-kappaB. , 2007, International journal of oncology.
[16] R. Kurzrock,et al. Nuclear factor-kappaB maintains TRAIL resistance in human pancreatic cancer cells. , 2006, Molecular cancer therapeutics.
[17] T. Niki,et al. A selective novel low‐molecular‐weight inhibitor of IκB kinase‐β (IKK‐β) prevents pulmonary inflammation and shows broad anti‐inflammatory activity , 2005 .
[18] S. Bailey,et al. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. , 2007, Molecular cancer therapeutics.
[19] Y. Kaneda,et al. Suppressed severity of collagen-induced arthritis by in vivo transfection of nuclear factor kappaB decoy oligodeoxynucleotides as a gene therapy. , 1999, Arthritis and rheumatism.
[20] James R. Burke,et al. BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.
[21] J. Christman,et al. Duration and Intensity of NF-κB Activity Determine the Severity of Endotoxin-Induced Acute Lung Injury1 , 2006, Journal of Immunology.
[22] T. Niki,et al. Discovery of novel and selective IKK-beta serine-threonine protein kinase inhibitors. Part 1. , 2003, Bioorganic & medicinal chemistry letters.
[23] Y. Kaneda,et al. Nuclear factor κB decoy oligodeoxynucleotides prevent endotoxin‐induced fatal liver failure in a murine model , 2003 .
[24] A. Itai,et al. Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction , 2007 .
[25] J. Falck,et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. , 2001, Molecular pharmacology.
[26] A. Itai,et al. A new IkappaB kinase beta inhibitor prevents human breast cancer progression through negative regulation of cell cycle transition. , 2006, Cancer research.
[27] J. Schmid,et al. BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways , 2006, Clinical Cancer Research.
[28] M. Bentires-Alj,et al. Selective Blockade of NF-κB Activity in Airway Immune Cells Inhibits the Effector Phase of Experimental Asthma1 , 2004, Journal of Immunology.
[29] Dong-Hyun Kim,et al. A ginseng saponin metabolite suppresses tumor necrosis factor-α-promoted metastasis by suppressing nuclear factor-κB signaling in murine colon cancer cells , 2008 .
[30] A. Itai,et al. A novel NF-kappaB inhibitor, IMD-0354, suppresses neoplastic proliferation of human mast cells with constitutively activated c-kit receptors. , 2005, Blood.
[31] M. Caligiuri,et al. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. , 2004, Journal of the National Cancer Institute.
[32] Capucine Picard,et al. Inherited disorders of NF-κB-mediated immunity in man , 2004 .
[33] S. Gerondakis,et al. Genetic approaches in mice to understand Rel/NF-kappaB and IkappaB function: transgenics and knockouts. , 1999, Oncogene.
[34] R. Kurzrock,et al. Nuclear factor-κB maintains TRAIL resistance in human pancreatic cancer cells , 2006, Molecular Cancer Therapeutics.
[35] A. Itai,et al. A novel IkappaB kinase-beta inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. , 2006, American journal of respiratory and critical care medicine.
[36] M. Aoki,et al. Prevention and regression of atopic dermatitis by ointment containing NF-kB decoy oligodeoxynucleotides in NC/Nga atopic mouse model , 2002, Gene Therapy.
[37] M. Yao,et al. A Selective IKK-2 Inhibitor Blocks NF-κB-dependent Gene Expression in Interleukin-1β-stimulated Synovial Fibroblasts* , 2003, Journal of Biological Chemistry.
[38] Jen-kun Lin,et al. Suppression of lipopolysaccharide-induced nuclear factor-κB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IκB kinase activity in macrophages , 2000 .
[39] P. Barnes,et al. Repression of Inflammatory Gene Expression in Human Pulmonary Epithelial Cells by Small-Molecule IκB Kinase Inhibitors , 2007, Journal of Pharmacology and Experimental Therapeutics.
[40] Ruhang Tang,et al. IKKbeta inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury. , 2007, American journal of physiology. Heart and circulatory physiology.
[41] Dong-Hyun Kim,et al. A ginseng saponin metabolite suppresses tumor necrosis factor-alpha-promoted metastasis by suppressing nuclear factor-kappaB signaling in murine colon cancer cells. , 2008, Oncology reports.
[42] Michael Karin,et al. NF-kappaB: linking inflammation and immunity to cancer development and progression. , 2005, Nature reviews. Immunology.
[43] V. Imbert,et al. NF‐κB inhibition triggers death of imatinib‐sensitive and imatinib‐resistant chronic myeloid leukemia cells including T315I Bcr‐Abl mutants , 2009, International journal of cancer.
[44] Akiko Itai,et al. Antiallergic and Anti-Inflammatory Effects of a Novel IκB Kinase β Inhibitor, IMD-0354, in a Mouse Model of Allergic Inflammation , 2008, International Archives of Allergy and Immunology.
[45] A. Itai,et al. Inhibition of NF-{kappa}B improves left ventricular remodeling and cardiac dysfunction after myocardial infarction. , 2007, American journal of physiology. Heart and circulatory physiology.
[46] M. Isobe,et al. Tea catechins attenuate chronic ventricular remodeling after myocardial ischemia in rats. , 2007, Journal of molecular and cellular cardiology.
[47] J. Schmid,et al. BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.
[48] Simone Fulda,et al. Sensitization of neuroblastoma cells for TRAIL‐induced apoptosis by NF‐κB inhibition , 2009, International journal of cancer.
[49] J. F. Schindler,et al. Novel Insights into the Cellular Mechanisms of the Anti-inflammatory Effects of NF-κB Essential Modulator Binding Domain Peptides , 2010, The Journal of Biological Chemistry.
[50] Fajun Yang,et al. The Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate Blocks Nuclear Factor-κB Activation by Inhibiting IκB Kinase Activity in the Intestinal Epithelial Cell Line IEC-6 , 2001 .
[51] A. Itai,et al. Effect of nuclear factor-kappaB inhibition on rheumatoid fibroblast-like synoviocytes and collagen induced arthritis. , 2005, The Journal of rheumatology.
[52] S. Ghosh,et al. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex , 2000 .
[53] L. Staudt,et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[54] M. Isobe,et al. Dietary consumption of green tea catechins attenuate hyperlipidaemia-induced atherosclerosis and systemic organ damage in mice , 2005, Acta cardiologica.
[55] K. McIntyre,et al. A HIGHLY SELECTIVE INHIBITOR OF IκB KINASE, BMS-345541, AUGMENTS GRAFT SURVIVAL MEDIATED BY SUBOPTIMAL IMMUNOSUPPRESSION IN A MURINE MODEL OF CARDIAC GRAFT REJECTION , 2004, Transplantation.
[56] Hong-Jin Kim,et al. Active roles for inhibitory κB kinases α and β in nuclear factor-κB–mediated chemoresistance to doxorubicin , 2008, Molecular Cancer Therapeutics.
[57] E. Campo,et al. Selective Inhibition of IκB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level1 , 2007, The Journal of Immunology.
[58] Yukio Nakamura,et al. Genetic approaches in mice to understand Rel/NF-κB and IκB function: transgenics and knockouts , 1999, Oncogene.
[59] S. Horvath,et al. Prostate Stem Cell Antigen Is Overexpressed in Prostate Cancer Metastases , 2005, Clinical Cancer Research.
[60] M. Isobe,et al. Tea catechins attenuate ventricular remodeling and graft arterial diseases in murine cardiac allografts. , 2006, Cardiovascular research.
[61] R. Plevin,et al. Selective inhibition of inhibitory kappa B kinase‐β abrogates induction of nitric oxide synthase in lipopolysaccharide‐stimulated rat aortic smooth muscle cells , 2005, British journal of pharmacology.
[62] N. Munshi,et al. NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.
[63] A. Itai,et al. A novel IKK inhibitor suppresses heart failure and chronic remodeling after myocardial ischemia via MMP alteration. , 2008, Expert opinion on therapeutic targets.
[64] M. Yao,et al. A selective IKK-2 inhibitor blocks NF-kappa B-dependent gene expression in interleukin-1 beta-stimulated synovial fibroblasts. , 2003, The Journal of biological chemistry.
[65] S. Keslacy,et al. Inhibition of Tumor Necrosis Factor-α-Inducible Inflammatory Genes by Interferon-γ Is Associated with Altered Nuclear Factor-κB Transactivation and Enhanced Histone Deacetylase Activity , 2006, Molecular Pharmacology.
[66] K. Chung,et al. Validation of the Anti-Inflammatory Properties of Small-Molecule IκB Kinase (IKK)-2 Inhibitors by Comparison with Adenoviral-Mediated Delivery of Dominant-Negative IKK1 and IKK2 in Human Airways Smooth Muscle , 2006, Molecular Pharmacology.
[67] A. Itai,et al. A Novel IκB Kinase-β Inhibitor Ameliorates Bleomycin-induced Pulmonary Fibrosis in Mice , 2006 .
[68] N. Munshi,et al. NF-kappa B as a therapeutic target in multiple myeloma. , 2002, The Journal of biological chemistry.
[69] S. Ghosh,et al. Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. , 2005, Arthritis and rheumatism.
[70] K. L. Gardner,et al. Interplay of IKK/NF-kappaB signaling in macrophages and myofibers promotes muscle degeneration in Duchenne muscular dystrophy. , 2007, The Journal of clinical investigation.
[71] T. Ogihara,et al. In vivo transfection of cis element “decoy” against nuclear factor- κB binding site prevents myocardial infarction , 1997, Nature Medicine.
[72] C. Trautwein,et al. Pharmacological IKK2 inhibition blocks liver steatosis and initiation of non-alcoholic steatohepatitis , 2008, Gut.
[73] N. Matsuda,et al. Nuclear Factor-κB Decoy Oligodeoxynucleotides Prevent Acute Lung Injury in Mice with Cecal Ligation and Puncture-Induced Sepsis , 2005, Molecular Pharmacology.
[74] S. Iida,et al. Growth Inhibition of Multiple Myeloma Cells by a Novel IκB Kinase Inhibitor , 2005, Clinical Cancer Research.
[75] C. Hunter,et al. NF-κB Family of Transcription Factors: Central Regulators of Innate and Adaptive Immune Functions , 2002, Clinical Microbiology Reviews.
[76] K. McIntyre,et al. BMS-345541 is a highly selective inhibitor of I kappa B kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. , 2003, The Journal of biological chemistry.
[77] V. Imbert,et al. AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells , 2003, Oncogene.
[78] T. Niki,et al. A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. , 2005, British journal of pharmacology.
[79] Koji Okabe,et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo , 2004, Nature Medicine.
[80] T. Ogihara,et al. Intravenous injection of oligodeoxynucleotides to the NF-kappaB binding site inhibits hepatic metastasis of M5076 reticulosarcoma in mice , 2001, Gene Therapy.
[81] Ruhang Tang,et al. IKKβ inhibition attenuates myocardial injury and dysfunction following acute ischemia-reperfusion injury , 2007 .
[82] F. Greten,et al. IKK/NF‐κB and STAT3 pathways: central signalling hubs in inflammation‐mediated tumour promotion and metastasis , 2009, EMBO reports.
[83] B. Ma,et al. Inhibition of NF-kappaB activation reduces the tissue effects of transgenic IL-13. , 2007, Journal of immunology.
[84] S. Iida,et al. Induction of cell death in adult T-cell leukemia cells by a novel IκB kinase inhibitor , 2006, Leukemia.
[85] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[86] K. Anderson,et al. Cytokines modulate telomerase activity in a human multiple myeloma cell line. , 2002, Cancer research.
[87] N. Munshi,et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. , 2003, Blood.
[88] J. Pober,et al. Selective inhibition of NF-kappaB activation by a peptide that blocks the interaction of NEMO with the IkappaB kinase complex. , 2000, Science.
[89] A. Itai,et al. Aldosterone-induced kidney injury is mediated by NFκB activation , 2010, Clinical and Experimental Nephrology.
[90] A. Itai,et al. Inhibition of IκB phosphorylation in cardiomyocytes attenuates myocardial ischemia/reperfusion injury , 2004 .
[91] B. Ma,et al. Inhibition of NF-κB Activation Reduces the Tissue Effects of Transgenic IL-131 , 2007, The Journal of Immunology.
[92] Fajun Yang,et al. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. , 2001, Molecular pharmacology.
[93] T. Yoshino,et al. Synthesis and structure-activity relationships of novel IKK-beta inhibitors. Part 3: Orally active anti-inflammatory agents. , 2004, Bioorganic & medicinal chemistry letters.
[94] S. Iida,et al. Growth inhibition of multiple myeloma cells by a novel IkappaB kinase inhibitor. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[95] S. Ghosh,et al. The NF-kappaB family of transcription factors and its regulation. , 2009, Cold Spring Harbor perspectives in biology.
[96] P. Richardson,et al. Biologic sequelae of c-Jun NH2-terminal kinase (JNK) activation in multiple myeloma cell lines , 2003, Oncogene.
[97] C. Sawyers,et al. IκB kinase β inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells , 2008, Molecular Cancer Therapeutics.
[98] R. Weichselbaum,et al. Diverse TNFα-induced death pathways are enhanced by inhibition of NF-κB , 2007 .
[99] M. Isobe,et al. Tea catechins improve left ventricular dysfunction, suppress myocardial inflammation and fibrosis, and alter cytokine expression in rat autoimmune myocarditis , 2007, European journal of heart failure.
[100] Y. Chiba,et al. IL-13 induces translocation of NF-kappaB in cultured human bronchial smooth muscle cells. , 2009, Cytokine.
[101] A. Itai,et al. Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice. , 2007, The Journal of investigative dermatology.
[102] B. Mellado,et al. Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity , 2006, Clinical Cancer Research.